doxorubicin-peptide conjugates (Bristol-Myers Squibb)

N/A

Report date: 2025/03/18 20:00:05
NME

Base Information

Drug Namedoxorubicin-peptide conjugates (Bristol-Myers Squibb)
Drug Alias NameN/A
ClassificationSmall molecules > Prodrug > Directed prodrug therapy
Mechanisms of ActionVirus DNA polymerase inhibitorsDNA intercalatorsTopoisomerase II inhibitors
TargetsTopoisomerase IIDNAVirus DNA polymerase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A